{"commentary":{"count":14,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":14},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03425643\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03425643","nct_id":"NCT03425643","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03425643. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, intravenous (IV); given on cycle day 1\\] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, IV; given on cycle day 1\\].","label":"NAC + Neoadjuvant/Adjuvant Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\] in combination with platinum doublet NAC, consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\].","label":"NAC + Neoadjuvant/Adjuvant Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-10-15","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":797,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Placebo","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"}],"last_update":"2026-07-29","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-07-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event Free Survival (EFS)","timeFrame":"Up to approximately 5 years"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 5 years"}],"references":[{"citation":"Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodriguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14.","pmid":"39288781","type":"RESULT"},{"citation":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodriguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3.","pmid":"37272513","type":"RESULT"},{"citation":"Tsuboi M, Saji H, Okada M, Ikeda N, Takamochi K, Sugio K, Horio Y, Tanaka F, Nishio W, Muto S, Horinouchi H, Wakelee H, Han S, Mori T, Keller SM, Kato T. Perioperative Pembrolizumab in Japanese Participants With Early-Stage NSCLC: Subgroup Analysis From KEYNOTE-671. JTO Clin Res Rep. 2026 May 2;7(10):101009. doi: 10.1016/j.jtocrr.2026.101009. eCollection 2026 Oct.","pmid":"42774586","type":"DERIVED"},{"citation":"Wakelee H, Spicer JD, Gao S, Liberman M, Tsuboi M, Kato T, Chen KN, Dooms C, Majem M, Martinengo GL, Bylicki O, Rodriguez-Abreu D, Halmos B, Jones DR, Chaft JE, Reck M, Jensen E, Keller SM, Samkari A, Garassino MC. Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study. Ann Oncol. 2026 Aug 21:S0923-7534(26)01462-6. doi: 10.1016/j.annonc.2026.08.005. Online ahead of print.","pmid":"42628840","type":"DERIVED"},{"citation":"Tsuboi M, Wakelee H, Garassino MC, Gao S, Luft A, Chen KN, Spicer JD, Zhu Y, Saji H, Okada M, Vanakesa T, Chen H, Zhao G, Ikeda N, Jones DR, Weksler B, Huang CS, Jensen E, Keller SM, Samkari A, Liberman M. A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study. Eur J Cardiothorac Surg. 2026 Mar 10;68(3):ezag028. doi: 10.1093/ejcts/ezag028.","pmid":"41875364","type":"DERIVED"},{"citation":"Aredo JV, Wakelee HA. Top advances of the year: Perioperative therapy for lung cancer. Cancer. 2024 Sep 1;130(17):2897-2903. doi: 10.1002/cncr.35357. Epub 2024 May 8.","pmid":"38717993","type":"DERIVED"},{"citation":"Romero Roman A, Campo-Canaveral de la Cruz JL, Macia I, Escobar Campuzano I, Figueroa Almanzar S, Delgado Roel M, Galvez Munoz C, Garcia Fontan EM, Muguruza Trueba I, Romero Vielva L, Cano Garcia JR, Martinez Tellez E, Partida Gonzalez C, Jimenez Lopez MF, Jimenez Maestre U, Mongil Poce R, Sanchez Lorente D, Alvarez Kindelan A, Provencio Pulla M. Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer. Eur J Cardiothorac Surg. 2021 Jul 14;60(1):81-88. doi: 10.1093/ejcts/ezab007.","pmid":"33661301","type":"DERIVED"}],"start_date":{"date":"2018-04-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)","url":"https://clinicaltrials.gov/study/NCT03425643"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03425643"}